Fluoroquinolones are a class of antibiotics frequently and globally prescribed as a measure to cure bacterial infections in humans and animals.  Most people are unaware that fluoroquinolones can be used in surgical procedures via IV and given for prophylactic measures.  There is an extensive list of drugs in this class in all forms, but the most familiar in the U.S. are the systemic generics such as levofloxacin, ciprofloxacin, moxifloxacin, ofloxacin and name brand Cipro.

Over the last decade, U.S. and the European Union regulators slowly started to strengthen fluoroquinolone safety warnings. The Food & Drug Administration (FDA) black boxed warnings and revised labeling state that systemic fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that can occur together, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and the worsening of myasthenia gravis. FDA warnings and labeling also address psychiatric and neurologic effects, serious blood sugar disturbances, increased risk of aortic aneurysm or dissection in certain patients, and ciprofloxacin’s inhibition of CYP1A2.  The European Medicines Agency (EMA) and PRAC communications warn that fluoroquinolones can be associated with prolonged, serious, disabling, and potentially irreversible adverse reactions affecting several, sometimes multiple, systems, organ classes, and senses.  Following PRAC’s safety review, the EMA further identified affected areas including the musculoskeletal system, nervous system, psychiatric health, and the senses, with examples such as tendonitis, tendon rupture, joint or limb pain, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impaired hearing, vision, taste, or smell.       

In recent years, scientific evidence has grown showing that fluoroquinolones may interfere with mitochondria, the energy-producing structures inside cells. While direct published research in affected patients is still urgently needed, laboratory findings suggest that ciprofloxacin and levofloxacin can disrupt mitochondrial function in more than one way. Ciprofloxacin may interfere with how mitochondria copy and maintain their own DNA, while both ciprofloxacin and levofloxacin may affect mitochondrial proteins involved in energy production and stress responses. Because mitochondria help power nerves, muscles, the brain, and nearly every system in the body, these findings help support a biologically plausible explanation for mitochondrial stress, impaired cell function, and disrupted energy production after fluoroquinolone exposure. Since mitochondrial dysfunction is increasingly linked to many chronic and degenerative diseases, these changes may represent an early biological warning sign, or prelude, to more serious disease processes over time. 

Fluoroquinolone residues have been documented in environmental and agricultural settings, including wastewater, surface waters, sediments, soils, manure-amended fields, livestock and poultry production environments, and some animal-derived foods.  Governments, the global public, and medical communities remain largely uninformed about a growing worldwide silent epidemic of individuals experiencing extensive adverse drug reactions, often alongside multiple medical complications, that are frequently misdiagnosed, dismissed, or never properly diagnosed.

In 2023, more than 14 million outpatient fluoroquinolone prescriptions were reportedly dispensed from U.S. community pharmacies, a figure that does not fully capture inpatient hospital or nursing home use, IV administration, or prescriptions from some federal facilities. This occurred despite FDA warnings about disabling and potentially permanent side effects. The true rate of persistent, multisystem injury remains unknown, especially after repeated exposure, IV use, or in patients with vulnerabilities that may affect drug metabolism, detoxification, mitochondrial function, or cellular repair. Even if only a small fraction of exposed patients developed persistent injury, the prescribing volume means the number of affected Americans could range in the tens of thousands. Because adverse drug reactions are substantially underreported, with some estimates suggesting that fewer than 1% are reported to the FDA, many patients may be living with fluoroquinolone toxicity without recognition or support.  The estimates for some other countries could be even higher due to the lack of prescription requirements, medication warnings, awareness, and data tracking.